{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-117148","form_type":"8-K","ticker":"MRKR","cik":"0001094038","company_name":"Marker Therapeutics, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.587925+00:00","generated_at":"2026-06-21T22:12:57.370560+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Marker Therapeutics Q3 net loss narrows to $6.9M; FDA grant awarded for AML trial","bullets":["Net loss of $6.9M in Q3 2022, compared to $12.4M loss in Q3 2021.","Cash and equivalents $18.1M as of Sept 30, 2022; grant income $1.0M, related party service revenue $2.95M.","Awarded $2M FDA Orphan Products Grant to support Phase 2 ARTEMIS trial of MT-401 in post-transplant AML.","All six patients in Cohorts 4/5 treated with new manufacturing process; no DLTs; efficacy data expected by year-end.","FDA cleared IND for Phase 1 MT-601 in relapsed/refractory non-Hodgkin lymphoma; first patient expected Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-117148","json":"https://secwatch.observer/filing/0001104659-22-117148.json","markdown":"https://secwatch.observer/filing/0001104659-22-117148.md","text":"https://secwatch.observer/filing/0001104659-22-117148.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1094038/000110465922117148/0001104659-22-117148-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1094038/000110465922117148/tm2223865d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:12:57.370560+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9954b76977b24cfec247ff2185463bbbc00a291d","claim":"Marker Therapeutics, Inc. reported the quarter ended September 30, 2022 results: net income $6.9 million.","evidence_excerpt":"Marker reported a net loss of $6.9 million for the quarter ended September 30, 2022, compared to a net loss of $12.4 million for the quarter ended September 30, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1094038/000110465922117148/0001104659-22-117148-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Net income","value":"$6.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}